A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, June 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (52nd percentile)
Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

twitter: 5 X users

Citations

dimensions_citation: 21 Dimensions

Readers on

mendeley: 33 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 6 X posts from 5 X users, with an upper bound of 9,325 followers.

RT @ArndtVogel: 📢happy to share our ph 1/2 study of FGF401 and combination of FGF401 with spartalizumab https://t.co/QHQIfHtuWF ✅study met…

23 Jun 2022

Reply Repost Favourite

📢happy to share our ph 1/2 study of FGF401 and combination of FGF401 with spartalizumab https://t.co/QHQIfHtuWF ✅study mets primary endpoint and RP2D has been defined 👉moving forward with targeted therapies in #HCC, but still a long way... @OncoAlert

23 Jun 2022

Reply Repost Favourite

RT @JournalofExper1: Online!✅ A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with #he…

10 Jun 2022

Reply Repost Favourite

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with #hepatocellularcarcinoma or biomarker-selected solid tumors

06 Jun 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.